GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » Revenue
中文

Novo Nordisk A/S (Novo Nordisk A/S) Revenue

: $33,619 Mil (TTM As of Dec. 2023)
View and export this data going back to 1981. Start your Free Trial

Novo Nordisk A/S's revenue for the three months ended in Dec. 2023 was $9,636 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $33,619 Mil. Novo Nordisk A/S's Revenue per Share for the three months ended in Dec. 2023 was $2.15. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $7.48.

Good Sign:

Novo Nordisk A/S has shown predictable revenue and earnings growth.

During the past 12 months, the average Revenue per Share Growth Rate of Novo Nordisk A/S was 32.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was 24.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was 16.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was 10.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Novo Nordisk A/S's highest 3-Year average Revenue per Share Growth Rate was 127.90% per year. The lowest was -46.20% per year. And the median was 10.40% per year.


Novo Nordisk A/S Revenue Historical Data

The historical data trend for Novo Nordisk A/S's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18,150.05 20,758.41 21,394.93 25,196.71 33,982.12

Novo Nordisk A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,847.88 7,676.28 7,901.75 8,404.91 9,636.42

Competitive Comparison

For the Biotechnology subindustry, Novo Nordisk A/S's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk A/S Revenue Distribution

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's Revenue distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's Revenue falls into.



Novo Nordisk A/S Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $33,619 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novo Nordisk A/S  (NYSE:NVO) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Novo Nordisk A/S Revenue Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, DK-2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk A/S (Novo Nordisk A/S) Headlines